The next goal for weight loss drugs? Fewer injections

Article excerpt

Pharmaceutical companies are racing to develop less-frequent dosing schedules for GLP-1 weight loss drugs like semaglutide and tirzepatide, aiming for weekly or monthly injections instead of the current once-weekly regimen. Users report needle anxiety, injection-site reactions, and compliance challenges that limit adoption despite the drugs' proven effectiveness. Manufacturers are testing extended-release formulations and oral versions, with some candidates already in late-stage clinical trials. The shift reflects a crucial market insight: people may abandon effective weight loss treatments not because they don't work, but because the delivery method is burdensome. Success here could unlock billions in revenue and expand access to populations currently deterred by injection frequency.